CellCept
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
prevention of organ rejection inpatients undergoing heart transplants
General Information
CellCept when used in combination with cyclosporine and
corticosteroids has been approved for the prevention of organ
rejection inpatients undergoing heart transplants. CellCept has
previously been approved for the prevention of organ rejection in
kidney-transplant patients.
Side Effects
The principal adverse reactions associated with the
administration of Cell Cept include diarrhea, leukopenia (reduction
of white blood cells), sepsis, and vomiting, and there is evidence
of a higher frequency of certain types of infections.
